Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Cash (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Cash for 16 consecutive years, with -$917.8 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 5978.15% to -$917.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311.8 million through Dec 2025, up 683.42% year-over-year, with the annual reading at $311.8 million for FY2025, 683.42% up from the prior year.
  • Change in Cash for Q4 2025 was -$917.8 million at Dexcom, down from $676.6 million in the prior quarter.
  • The five-year high for Change in Cash was $676.6 million in Q3 2025, with the low at -$917.8 million in Q4 2025.
  • Average Change in Cash over 5 years is $5.0 million, with a median of -$17.0 million recorded in 2023.
  • The sharpest move saw Change in Cash surged 2862.18% in 2023, then tumbled 5978.15% in 2025.
  • Over 5 years, Change in Cash stood at -$391.6 million in 2021, then skyrocketed by 85.75% to -$55.8 million in 2022, then plummeted by 38.53% to -$77.3 million in 2023, then soared by 80.47% to -$15.1 million in 2024, then crashed by 5978.15% to -$917.8 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$917.8 million, $676.6 million, and $254.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.